Evidence map›Paper›PMID 38333854›Full record

ArticleHeliyon2024

Glucose-lowering effect of Reducose® enriched with 1-deoxynojirimycin and l-leucine: Studies on insulin secretion in INS-1 cells and reduction of blood glucose in diabetic rats.

Dahae Lee, Ji Yun Baek, Ye Jung Choi, Min Ji Han, Seon Hwa Kim, Tae Hoon Kim, Sanghyun Lee, Ki Sung Kang

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Dahae LeeCollege of Korean Medicine, Gachon University, Seongnam, 13120, Republic of Korea.
Ji Yun BaekCollege of Korean Medicine, Gachon University, Seongnam, 13120, Republic of Korea.
Ye Jung ChoiCollege of Korean Medicine, Gachon University, Seongnam, 13120, Republic of Korea.
Min Ji HanVixxol Corporation, Gunpo, 15807, Republic of Korea.
Seon Hwa KimVixxol Corporation, Gunpo, 15807, Republic of Korea.
Tae Hoon KimVixxol Corporation, Gunpo, 15807, Republic of Korea.
Sanghyun LeeDepartment of Plant Science and Technology, Chung-Ang University, Anseong, 17546, Republic of Korea.
Ki Sung KangCollege of Korean Medicine, Gachon University, Seongnam, 13120, Republic of Korea.
Gachon University · KRChung-Ang University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The extract of mulberry leaf and its active ingredients have already been reported to have anti-diabetic effects; however, further studies are required to obtain better quality extracts and higher yields of active ingredients. Reducose® is a commercially available aqueous extract of mulberry leaves with a high content of active ingredients. In this study, the biological activities of Reducose®, 1-deoxynojirimycin, and l-leucine were evaluated using a glucose-stimulated insulin secretion (GSIS) assay. The GSIS assay results were expressed as the glucose-stimulated index (GSI). Considering the pharmacological safety in pancreatic β-cells, the appropriate non-toxic concentrations were selected by screening for cytotoxicity of Reducose®, 1-deoxynojirimycin, and l-leucine before the GSIS assay. The effect of Reducose®, 1-deoxynojirimycin, and l-leucine on glucose-stimulated insulin secretion in INS-1 cells was compared. Reducose®, 1-deoxynojirimycin, and l-leucine increased the GSI values more effectively than gliclazide (positive control). This was associated with an increase in protein expression, such as peroxisome proliferator-activated receptor-γ, insulin receptor substrate-2, activated pancreatic and duodenal homeobox-1, which are related to the regulation of pancreatic β-cell function and survival. In order to elucidate the effect of Reducose® in anti-diabetic effects, blood glucose levels, insulin levels, and liver and lipid concentrations were investigated in a Sprague-Dawley rat model of high-fat diet/streptozotocin-induced diabetes. We observed that administration of Reducose® can decrease fasting blood glucose levels and reduce the production of AST, ALT, TG, and TC to a similar extent as metformin (positive control). These results suggested that Reducose® play a role in promoting GSIS but not enough to show that the content and proportion of 1-deoxynojirimycin and l-leucine play an important role in the GSIS activity of Reducose®.

Indexed as

1-DeoxynojirimycinGlucoseInsulin secretionl-leucineReducose®

Identifiers

PMID38333854
PMCPMC10850582
OpenAlexW4391451735

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.